About  Us

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

About  Us

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

​Putting together the brightest minds involved in basic science, drug development, medical practice and commercialization to develop new cures in the most rapid means possible.

​Putting together the brightest minds involved in basic science, drug development, medical practice and commercialization to develop new cures in the most rapid means possible.

Disease  Indications

Solid Tumors (Various)

Breast Cancer

Liver Cancer

Myelodysplastic Syndrome

Leukemia

Bone Marrow Disorders

Solid Tumors (Various)

Breast Cancer

Liver Cancer

Myelodysplastic Syndrome

Leukemia

Bone Marrow Disorders

Regen BioPharma has multiple technologies targeting various types of cancer and disorders of the immune system.

Disease  Indications

Solid Tumors (Various)

Breast Cancer

Liver Cancer

Myelodysplastic Syndrome

Leukemia

Bone Marrow Disorders

Regen BioPharma has multiple technologies targeting various types of cancer and disorders of the immune system.

Our Team

Management Team 

David R. Koos, PhD, DBA

Chairman & CEO

David Koos has over 30 years of investment banking and venture capital experience.  

David R. Koos, PhD, DBA

Chairman & CEO

20210524-134816_orig

David R. Koos, PhD, DBA

Chairman & CEO

David Koos has over 30 years of investment banking and venture capital experience...
20210524-134816_orig

David R. Koos, PhD, DBA

Chairman & CEO

Scientific Advisory Board 

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

Ravinder Reddy, Ph.D.

Dr. Reddy is currently a Professor of Radiology and the Director of the Center for Advanced Metabolic Imaging in Prec...

Mohammad Haris, Ph.D.

Dr. Haris is an Associate Professor in the Center for Advanced Metabolic Imaging in Precision Medicine, Department of...

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell Biology and has been named Executi...

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejec...

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah.

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center, and the Translational Neuro-Oncology Labo...

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer ste...

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids. He...

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the disco...

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’) of the French Natio...

Ravinder Reddy, Ph.D.

Dr. Reddy is currently a Professor of Radiology and the Director of the Center for Advanced Metabolic Imaging in Precision Medicine

Ravinder Reddy, Ph.D.

Dr. Reddy is currently a Professor of Radiology and the Director of the Center for Advanced Metabolic Imaging in Precision Medicine

Mohammad Haris, Ph.D.

Dr. Haris is an Associate Professor in the Center for Advanced Metabolic Imaging in Precision Medicine, Department of Radiology, 

Mohammad Haris, Ph.D.

Dr. Haris is an Associate Professor in the Center for Advanced Metabolic Imaging in Precision Medicine,

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection.

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection.

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. 

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. 

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center
 

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center
 

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. 

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. 

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’)

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’)

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

Our Team

Management Team 

David R. Koos, PhD, DBA

Chairman & CEO

David Koos has over 30 years of investment banking and venture capital experience.  

David R. Koos, PhD, DBA

Chairman & CEO

Scientific Advisory Board 

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell.

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
 

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection.

Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection.

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. 

Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. 

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center
 

Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center
 

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. 

Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. 

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’)

Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’)

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids.

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines

Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines

Intellectual Property –  Issued Patents

Patent Number
Patent Title
Date Granted
US-11,324,719-B2
Small molecule agonists and antagonists of NR2F6 activity in humans
2022-10-05
US-11,241,427-B2
Small molecule modulators of NR2F6 Activity
2022-02-08
US-11,141,471-B2
Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
2021-10-12
US-11,090,332-B2
Antigen specific mRNA cellular cancer vaccines
2021-08-17
US-11,053,503-B2
Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition
2021-07-06
US-10,088,485-B2
Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
2018-10-02
US-9,091,696-B2
Modulation of NR2F6 and methods and uses thereof
2015-07-28
US-8,389,708-B2
Method of cancer treatment using siRNA silencing
2013-03-05
US-8,263,571-B2
Gene silencing of the brother of the regulator of imprinted sites (BORIS)
2012-09-11